Sitagliptin for treating type 2 diabetes mellitus

Published on 01 Jul 2022
Last Updated on 01 Jul 2022

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• sitagliptin 25 mg, 50 mg and 100 mg tablets

in line with their registered indications for improving glycemic control in patients with type 2 diabetes mellitus, in view of acceptable price proposal from the manufacturer.

Subsidy status

Sitagliptin 25 mg, 50 mg and 100 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

SDL subsidy does not apply to combination products containing sitagliptin or other DPP-4 inhibitors.

Sitagliptin for treating type 2 diabetes mellitus (1 Jul 22) [PDF, 103 KB]